YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)

Publication | Open Access

DOI Full Paper Access

Citations

References

2017

Year

Antonio Cubillo Gracián, Andrew Dean, Andrés Muñoz, Manuel Hidalgo, Roberto Pazo-Cid, M. Martín, T. Macarulla Mercadé, Lara Lipton, Marion Harris, J.L. Manzano-Mozo,

Annals of Oncology

Arm Double-blindTruncated CoursesTherapeutic VaccineBiological TherapyBiomedical EngineeringPharmacologyPaclitaxel Protein-bound ParticlesNovel Therapy